{"title":"Gulf between research evidence and clinical reality in relation to prescribing in EUPD","authors":"D. Yadav","doi":"10.1002/pnp.792","DOIUrl":"https://doi.org/10.1002/pnp.792","url":null,"abstract":"","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41519959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This article presents a case of classical tardive dyskinesia, apparent since at least 1997 when tetrabenazine and clonazepam were prescribed to the patient in addition to risperidone. However, the patient's mental health had been well controlled until sudden cessation of risperidone and the subsequent development of severe classical tardive dyskinesia, tardive dystonia and tardive tics. The authors describe the proposed pathophysiology of tardive dyskinesia, the impure nature of tardive syndromes, the underdiagnosis of tardive tics but eventual successful treatment with quetiapine.
{"title":"Heterogeneous tardive syndromes are still treatable with quetiapine","authors":"M. Curran, Edward Mellor, Sally Howarth","doi":"10.1002/pnp.787","DOIUrl":"https://doi.org/10.1002/pnp.787","url":null,"abstract":"This article presents a case of classical tardive dyskinesia, apparent since at least 1997 when tetrabenazine and clonazepam were prescribed to the patient in addition to risperidone. However, the patient's mental health had been well controlled until sudden cessation of risperidone and the subsequent development of severe classical tardive dyskinesia, tardive dystonia and tardive tics. The authors describe the proposed pathophysiology of tardive dyskinesia, the impure nature of tardive syndromes, the underdiagnosis of tardive tics but eventual successful treatment with quetiapine.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42572473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Javaid, S. Rasool, Zaid Hamid, D. Michael, Anam Amir
{"title":"Impact of COVID‐19 on rate of admissions in the Humber Teaching NHS Foundation Trust in Yorkshire","authors":"A. Javaid, S. Rasool, Zaid Hamid, D. Michael, Anam Amir","doi":"10.1002/pnp.793","DOIUrl":"https://doi.org/10.1002/pnp.793","url":null,"abstract":"","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46396684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The United Nations described violence against women and girls during the global outbreak of COVID‐19 as a ‘shadow pandemic’; perpetrators were said to have ‘weaponised’ national measures and restrictions, exacerbating domestic abuse. However, evidence for the prevalence of domestic violence and abuse (DVA) during COVID‐19 and its impact on the mental health of victim‐survivors is limited by the extent to which it was measured by research studies and the quality of methods that could be feasibly implemented. This review reports what is currently known about global DVA prevalence during the pandemic and its impact on mental health. It summarises key guidance for clinicians assessing patients during periods of social distancing and proposes recommendations for the ‘new normal’ and future pandemics.
{"title":"Domestic violence and mental health during COVID‐19","authors":"R. Keynejad","doi":"10.1002/pnp.783","DOIUrl":"https://doi.org/10.1002/pnp.783","url":null,"abstract":"The United Nations described violence against women and girls during the global outbreak of COVID‐19 as a ‘shadow pandemic’; perpetrators were said to have ‘weaponised’ national measures and restrictions, exacerbating domestic abuse. However, evidence for the prevalence of domestic violence and abuse (DVA) during COVID‐19 and its impact on the mental health of victim‐survivors is limited by the extent to which it was measured by research studies and the quality of methods that could be feasibly implemented. This review reports what is currently known about global DVA prevalence during the pandemic and its impact on mental health. It summarises key guidance for clinicians assessing patients during periods of social distancing and proposes recommendations for the ‘new normal’ and future pandemics.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45355844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The combination of type 1 diabetes and bulimia nervosa has been referred to as ‘diabulimia’. The prognosis is poorer in subjects with comorbid disorder than those with isolated bulimia nervosa. Collaborative, integrated care is needed in the assessment and treatment of patients. In this review article we provide a formulation merging both the transdiagnostic and dual pathway models and discuss the latest evidence‐based management for patients with coexisting diagnoses.
{"title":"‘Diabulimia’: current insights into type 1 diabetes and bulimia nervosa","authors":"A. Yahya, Shakil Khawaja, Meena Naguib","doi":"10.1002/pnp.782","DOIUrl":"https://doi.org/10.1002/pnp.782","url":null,"abstract":"The combination of type 1 diabetes and bulimia nervosa has been referred to as ‘diabulimia’. The prognosis is poorer in subjects with comorbid disorder than those with isolated bulimia nervosa. Collaborative, integrated care is needed in the assessment and treatment of patients. In this review article we provide a formulation merging both the transdiagnostic and dual pathway models and discuss the latest evidence‐based management for patients with coexisting diagnoses.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42966430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
wchh.onlinelibrary.wiley.com 4 I Progress in Neurology and Psychiatry I Vol. 27 Iss. 1 2023 Since the development of the ‘amyloid hypothesis1–3 there has been considerable effort in developing treatments that target the build-up of amyloid beta (Aβ) plaques in the brain thought to be responsible for Alzheimer’s disease (AD). Over the past 15 years, much of this research has focussed on developing monoclonal antibodies as potential disease modifying treatments (DMTs) targeting Aβ.4 However, a number of trials of similar molecules did not meet the primary endpoint or were pulled midway after interim futility analyses,5–7 leading to questions about whether this was the right approach given the complex and multifactorial pathogenesis of AD. An exception to this was the USA’s Food and Drug Administration (FDA) accelerated approval for aducanumab in June 2021, which we reviewed here previously.8 Accelerated approval was designed to allow for earlier authorisation of drugs that are intended to treat serious conditions where the initial evidence showed the potential to address an unmet clinical need. There is still a requirement for phase 4 confirmatory trials, which in the case of aducanumab are ongoing. The decision to grant accelerated approval for aducanumab was controversial due to doubts regarding clinical efficacy – that it was based on post hoc analysis of data, and also safety concerns. The decision led to several members of the FDA advisory team resigning in protest.9
{"title":"Lecanemab for Alzheimer's disease: new hope or another false dawn?","authors":"Mark Dashwood, T. Kuruvilla","doi":"10.1002/pnp.772","DOIUrl":"https://doi.org/10.1002/pnp.772","url":null,"abstract":"wchh.onlinelibrary.wiley.com 4 I Progress in Neurology and Psychiatry I Vol. 27 Iss. 1 2023 Since the development of the ‘amyloid hypothesis1–3 there has been considerable effort in developing treatments that target the build-up of amyloid beta (Aβ) plaques in the brain thought to be responsible for Alzheimer’s disease (AD). Over the past 15 years, much of this research has focussed on developing monoclonal antibodies as potential disease modifying treatments (DMTs) targeting Aβ.4 However, a number of trials of similar molecules did not meet the primary endpoint or were pulled midway after interim futility analyses,5–7 leading to questions about whether this was the right approach given the complex and multifactorial pathogenesis of AD. An exception to this was the USA’s Food and Drug Administration (FDA) accelerated approval for aducanumab in June 2021, which we reviewed here previously.8 Accelerated approval was designed to allow for earlier authorisation of drugs that are intended to treat serious conditions where the initial evidence showed the potential to address an unmet clinical need. There is still a requirement for phase 4 confirmatory trials, which in the case of aducanumab are ongoing. The decision to grant accelerated approval for aducanumab was controversial due to doubts regarding clinical efficacy – that it was based on post hoc analysis of data, and also safety concerns. The decision led to several members of the FDA advisory team resigning in protest.9","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43072620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Ansari, Marlene Kelbrick, Gabriela Paduret, N. Diaz, Rose Menzel, R. Rogers, Claire Wareham, Chris Griffiths, Sue Jugon, Katy Tidy, Sara Johnson, Nick Mann, James Tanner, Timothy Millward, Shahid Latif
National and local guidelines focus mainly on clozapine monitoring frequency, and actions based on full blood count results. Prescribing clozapine in the context of COVID‐19‐positive patients brings a complexity of challenge beyond this. In this article the authors put forward an example of a practical clinical guideline in this regard.
{"title":"Clinical practice guideline for clozapine use in patients with COVID‐19","authors":"S. Ansari, Marlene Kelbrick, Gabriela Paduret, N. Diaz, Rose Menzel, R. Rogers, Claire Wareham, Chris Griffiths, Sue Jugon, Katy Tidy, Sara Johnson, Nick Mann, James Tanner, Timothy Millward, Shahid Latif","doi":"10.1002/pnp.779","DOIUrl":"https://doi.org/10.1002/pnp.779","url":null,"abstract":"National and local guidelines focus mainly on clozapine monitoring frequency, and actions based on full blood count results. Prescribing clozapine in the context of COVID‐19‐positive patients brings a complexity of challenge beyond this. In this article the authors put forward an example of a practical clinical guideline in this regard.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48652542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The promotion and enabling of vulnerable and long‐stay inpatients’ sexualities is a largely neglected practice. This paper offers a novel contribution to the existing literature by considering the assessment of capacity to use sex toys. It describes the development of a set of guidelines and application of these in two clinical cases. It is hoped that the paper will provide a start point from which the guidelines could be scrutinised and refined by professional bodies and legal review.
{"title":"Considering capacity to use sex toys in secure care: two case reports","authors":"F. Shaddel, D. Mayes","doi":"10.1002/pnp.780","DOIUrl":"https://doi.org/10.1002/pnp.780","url":null,"abstract":"The promotion and enabling of vulnerable and long‐stay inpatients’ sexualities is a largely neglected practice. This paper offers a novel contribution to the existing literature by considering the assessment of capacity to use sex toys. It describes the development of a set of guidelines and application of these in two clinical cases. It is hoped that the paper will provide a start point from which the guidelines could be scrutinised and refined by professional bodies and legal review.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49077254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Patients with functional neurological symptoms (FNS) such as functional weakness and non‐epileptic attacks may present to acute hospital services. However, there are few good data on the proportion of neurological admissions they account for, or the utilisation of inpatient resources associated with them.
{"title":"Inpatient resources used in organic versus functional neurological disorders","authors":"H. Newman, Timothy Greig, Michael O’Gara","doi":"10.1002/pnp.777","DOIUrl":"https://doi.org/10.1002/pnp.777","url":null,"abstract":"Patients with functional neurological symptoms (FNS) such as functional weakness and non‐epileptic attacks may present to acute hospital services. However, there are few good data on the proportion of neurological admissions they account for, or the utilisation of inpatient resources associated with them.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48944055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sagari Gullapalli, Rithvik Ramesh, S. Shanmugam, P. Hazeena
MOG antibody disorder presenting as a combined central and peripheral demyelination (CCPD) is uncommon. CCPD has been associated with other primary demyelination syndromes such as multiple sclerosis, neuromyelitis optica or chronic inflammatory demyelinating polyneuropathy. Here, the authors describe the diagnosis and management of a 21‐year‐old female with historically sequential demyelinating plaques in her right thalamus, cervical cord, left optic nerve and electrophysiology suggestive of bilateral ulnar nerve demyelination.
{"title":"MOG antibody associated with central and peripheral demyelination","authors":"Sagari Gullapalli, Rithvik Ramesh, S. Shanmugam, P. Hazeena","doi":"10.1002/pnp.775","DOIUrl":"https://doi.org/10.1002/pnp.775","url":null,"abstract":"MOG antibody disorder presenting as a combined central and peripheral demyelination (CCPD) is uncommon. CCPD has been associated with other primary demyelination syndromes such as multiple sclerosis, neuromyelitis optica or chronic inflammatory demyelinating polyneuropathy. Here, the authors describe the diagnosis and management of a 21‐year‐old female with historically sequential demyelinating plaques in her right thalamus, cervical cord, left optic nerve and electrophysiology suggestive of bilateral ulnar nerve demyelination.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49564631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：